The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The Lysophosphatidic Acid Receptor LPA1 Promotes Epithelial Cell Apoptosis after Lung Injury
Open accessAbstract
Increased epithelial cell apoptosis in response to lung injury has been implicated in the development of idiopathic pulmonary fibrosis (IPF), but the molecular pathways promoting epithelial cell apoptosis in this disease have yet to be fully identified. Lysophosphatidic acid (LPA), which we have previously demonstrated to mediate bleomycin lung injury–induced fibroblast recruitment and vascular leak in mice and fibroblast recruitment in patients with IPF, is an important regulator of survival and apoptosis in many cell types. We now show that LPA signaling through its receptor LPA1 promotes epithelial cell apoptosis induced by bleomycin injury. The number of apoptotic cells present in the alveolar and bronchial epithelia of LPA1–deficient mice was significantly reduced compared with wild-type mice at Day 3 after bleomycin challenge, as was lung caspase-3 activity. Consistent with these in vivo results, we found that LPA signaling through LPA1 induced apoptosis in normal human bronchial epithelial cells in culture. LPA-LPA1 signaling appeared to specifically mediate anoikis, the apoptosis of anchorage-dependent cells induced by their detachment. Similarly, LPA negatively regulated attachment of R3/1 rat alveolar epithelial cell line cells. In contrast, LPA signaling through LPA1 promoted the resistance of lung fibroblasts to apoptosis, which has also been implicated in IPF. The ability of LPA-LPA1 signaling to promote epithelial cell apoptosis and fibroblast resistance to apoptosis may therefore contribute to the capacity of this signaling pathway to regulate the development of pulmonary fibrosis after lung injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257
LPA Receptors: Subtypes and Biological Actions
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C.-W., Mutoh, T., Lin, M.-E., Teo, S. T., Park, K. E., Mosley, A. N., et al. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105753 · Cited by 839
Self-citationTager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Self-citationGilmore, A. P. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401723 · Cited by 597
Inflammatory mediators in acute pancreatitis
Bhatia, M., Brady, M., Shokuhi, S., Christmas, S., Neoptolemos, J. P., & Slavin, J. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200002)190:2<117::aid-path494>3.0.co;2-k · Cited by 534
Anoikis: A necessary death program for anchorage-dependent cells
Chiarugi, P., & Giannoni, E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.023 · Cited by 494
Requirement for the lp A1 lysophosphatidic acid receptor gene in normal suckling behavior
Contos, J. J. A., Fukushima, N., Weiner, J. A., Kaushal, D., & Chun, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13384 · Cited by 479
Self-citationTargeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary Fibrosis
Sisson, T. H., Mendez, M., Choi, K., Subbotina, N., Courey, A., Cunningham, A., Dave, A., Engelhardt, J. F., Liu, X., White, E. S., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1615oc · Cited by 474
Research works printed but not linked: 1
- Funke, 2009, Lysophosphatidic acid contributes to an apoptosis paradox in lung fibrosis [abstract], Am J Respir Crit Care Med, A1988
Cited by
Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions
Della Latta, V., Cecchettini, A., Del Ry, S., & Morales, M. A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.012 · Cited by 514
New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
Fernandez, I. E., & Eickelberg, O. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61144-1 · Cited by 437
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 308
Cellular interactions in the pathogenesis of interstitial lung diseases
Bagnato, G., & Harari, S. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Koudstaal, T., Funke-Chambour, M., Kreuter, M., Molyneaux, P. L., & Wijsenbeek, M. S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.010 · Cited by 256
Lysophospholipids and their receptors in the central nervous system
Choi, J. W., & Chun, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.015 · Cited by 255
Self-citationPulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis
Oikonomou, N., Mouratis, M.-A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G. D., Bouros, D., & Aidinis, V. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0004oc · Cited by 250
Knipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Self-citationLysophosphatidic acid as a lipid mediator with multiple biological actions
Aikawa, S., Hashimoto, T., Kano, K., & Aoki, J. (2015) · Journal of Biochemistry · doi:10.1093/jb/mvu077 · Cited by 214
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways
Suryadevara, V., Ramchandran, R., Kamp, D. W., & Natarajan, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124257 · Cited by 165
Desroy, N., Housseman, C., Bock, X., Joncour, A., Bienvenu, N., Cherel, L., Labeguere, V., Rondet, E., Peixoto, C., Grassot, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00032 · Cited by 157
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 154
Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA · doi:10.1001/jama.2023.5355 · Cited by 148
Autotaxin in Pathophysiology and Pulmonary Fibrosis
Ninou, I., Magkrioti, C., & Aidinis, V. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00180 · Cited by 144
Therapeutic targets in idiopathic pulmonary fibrosis
Kolb, M. R. J., Bonella, F., & Wollin, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.062 · Cited by 141
Knipe, R. S., Probst, C. K., Lagares, D., Franklin, A., Spinney, J. J., Brazee, P. L., Grasberger, P. E., Zhang, L., Black, K. E., Sakai, N., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0075oc · Cited by 134
Self-citationRole of the autotaxin–lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy
Brindley, D. N., Lin, F., & Tigyi, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.08.015 · Cited by 131
Tissue remodelling in pulmonary fibrosis
Knudsen, L., Ruppert, C., & Ochs, M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2543-2 · Cited by 129
Huang, L. S., Sudhadevi, T., Fu, P., Kannan, P. K. P., Ebenezer, D. L., Ramchandran, R., Putherickal, V., Cheresh, P., Zhou, G., Ha, A. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062064 · Cited by 128
Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling
Zhao, Y., & Natarajan, V. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.06.014 · Cited by 124
Autotaxin and chronic inflammatory diseases
Magkrioti, C., Galaris, A., Kanellopoulou, P., Stylianaki, E.-A., Kaffe, E., & Aidinis, V. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102327 · Cited by 116
Huang, L. S., Fu, P., Patel, P., Harijith, A. K., Sun, T., Zhao, Y., Garcia, J. G. N., Chun, J. J. M., & Natarajan, V. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0070oc · Cited by 111
Self-citationMaher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 103
Targeting sphingosine kinase 1 attenuates bleomycin‐induced pulmonary fibrosis
Huang, L. S., Berdyshev, E. V., Mathew, B., Fu, P., Gorshkova, I. A., He, D., Ma, W., Noth, I., Ma, S., Pendyala, S., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-219634 · Cited by 98
Shea, B. S., & Tager, A. M. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-005aw · Cited by 95
Self-citationRindlisbacher, B., Schmid, C., Geiser, T., Bovet, C., & Funke-Chambour, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0714-2 · Cited by 93
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature
Castagna, D., Budd, D. C., Macdonald, S. J. F., Jamieson, C., & Watson, A. J. B. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01599 · Cited by 88
Sakai, N., Chun, J. J. M., Duffield, J. S., Lagares, D., Wada, T., Luster, A. D., & Tager, A. M. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.030 · Cited by 87
Self-citationTang, N., Zhao, Y., Feng, R., Liu, Y., Wang, S., Wei, W., Ding, Q., An, M. (., Wen, J., & Li, L. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12178 · Cited by 86
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy
Chen, R., & Dai, J. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02336-1 · Cited by 85
Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
Kaffe, E., Magkrioti, C., & Aidinis, V. (2019) · Cancers · doi:10.3390/cancers11111626 · Cited by 76
Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0977oc · Cited by 70
Kiss, G. N., Fells, J. I., Gupte, R., Lee, S.-C., Liu, J., Nusser, N., Lim, K. G., Ray, R. M., Lin, F., Parrill, A. L., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079699 · Cited by 70
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Montesi, S. B., Mathai, S. K., Brenner, L. N., Gorshkova, I. A., Berdyshev, E. V., Tager, A. M., & Shea, B. S. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-5 · Cited by 66
Self-citationQian, Y., Hamilton, M., Sidduri, A., Gabriel, S. D., Ren, Y., Peng, R., Kondru, R. K., Narayanan, A., Truitt, T., Hamid, R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301022v · Cited by 66
Lysophosphatidic Acid Receptors: Biochemical and Clinical Implications in Different Diseases
Xiang, H., Lu, Y., Shao, M., & Wu, T. (2020) · Journal of Cancer · doi:10.7150/jca.41841 · Cited by 65
Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases
Takuwa, Y., Ikeda, H., Okamoto, Y., Takuwa, N., & Yoshioka, K. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.06.008 · Cited by 63
Huang, L. S., Mathew, B., Li, H., Zhao, Y., Ma, S., Noth, I., Reddy, S. P., Harijith, A. K., Usatyuk, P. V., Berdyshev, E. V., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1917oc · Cited by 62
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001026 · Cited by 59
Autotaxin Emerges as a Therapeutic Target for Idiopathic Pulmonary Fibrosis
Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0235ed · Cited by 56
Self-citationXu, L., Su, J., Guo, L., Wang, S., Deng, X., & Ma, S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.027 · Cited by 55
Black, K. E., Berdyshev, E. V., Bain, G., Castelino, F. V., Shea, B. S., Probst, C. K., Fontaine, B. A., Bronova, I. A., Goulet, L., Lagares, D., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500197r · Cited by 53
Self-citationHarijith, A. K., Pendyala, S., Reddy, N. M., Bai, T., Usatyuk, P. V., Berdyshev, E. V., Gorshkova, I. A., Huang, L. S., Mohan, V., Garzon, S., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.06.018 · Cited by 53
Lysophosphatidic acid, a simple phospholipid with myriad functions
Yanagida, K., & Shimizu, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108421 · Cited by 51
Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo
Kuttruff, C. A., Ferrara, M., Bretschneider, T., Hoerer, S., Handschuh, S., Nosse, B., Romig, H., Nicklin, P. L., & Roth, G. J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00312 · Cited by 50
Lummis, N. C., Sánchez-Pavón, P., Kennedy, G., Frantz, A., Kihara, Y., Blaho, V. A., & Chun, J. J. M. (2019) · Science Advances · doi:10.1126/sciadv.aax2011 · Cited by 49
Self-citationBrindley, D. N., Tang, X., Meng, G., & Benesch, M. G. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165938 · Cited by 49
Fakhraee, S. H., Badiee, Z., Mojtahedzadeh, S., Kazemian, M., & Kelishadi, R. (2007) · PubMed · Cited by 48
van der Aar, E., Desrivot, J., Dupont, S., Heckmann, B., Fieuw, A. M., Stutvoet, S., Fagard, L., de Wal, K. V., & Helmer, E. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1424 · Cited by 43
GPR87 promotes renal tubulointerstitial fibrosis by accelerating glycolysis and mitochondrial injury
Cui, X., Shi, E., Li, J., Li, Y., Qiao, Z., Wang, Z., Liu, M., Tang, W., Sun, Y., Zhang, Y., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.004 · Cited by 42
Nadhan, R., Nath, K., Basu, S., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02423-4 · Cited by 40
Development of Lysophosphatidic Acid Pathway Modulators as Therapies for Fibrosis
Budd, D. C., & Qian, Y. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.154 · Cited by 38
Idiopathic pulmonary fibrosis: the turning point is now!
Funke, M., & Geiser, T. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14139 · Cited by 38
Self-citationZhao, J., Wei, J., Weathington, N. M., Jacko, A. M., Huang, H., Tsung, A., & Zhao, Y. (2015) · Translational research · doi:10.1016/j.trsl.2015.01.008 · Cited by 38
Sakai, N., Bain, G., Furuichi, K., Iwata, Y., Nakamura, M., Hara, A., Kitajima, S., Sagara, A., Miyake, T., Toyama, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43576-x · Cited by 37
New therapeutics based on emerging concepts in pulmonary fibrosis
Sontake, V., Gajjala, P. R., Kasam, R. K., & Madala, S. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1552262 · Cited by 34
Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases
Jiang, S., Yang, H., & Li, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512524 · Cited by 34
Mitigation of radiation injury by selective stimulation of the LPA2 receptor
Kiss, G. N., Lee, S.-C., Fells, J. I., Liu, J., Valentine, W. J., Fujiwara, Y., Thompson, K. E., Yates, C. R., Sümegi, B., & Tigyi, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.08.020 · Cited by 34
Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: In vivo and in vitro evidence
Rancoule, C., Viaud, M., Grès, S., Viguerie, N., Decaunes, P., Bouloumié, A., Langin, D., Bascands, J., Valet, P., & Saulnier‐Blache, J. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.003 · Cited by 34
Murray, L. A., Rubinowitz, A. N., & Herzog, E. L. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283588de4 · Cited by 33
Fibrogenic Lung Injury Induces Non–Cell-Autonomous Fibroblast Invasion
Ahluwalia, N., Grasberger, P. E., Mugo, B. M., Feghali‐Bostwick, C. A., Pardo, A., Selman, M., Lagares, D., & Tager, A. M. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0040oc · Cited by 33
Self-citationZhao, J., Wei, J., Dong, S., Bowser, R. K., Zhang, L., Jacko, A. M., & Zhao, Y. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.020 · Cited by 33
A metabolomic approach to elucidate the inhibitory effects of baicalin in pulmonary fibrosis
Chang, H., Meng, H.-Y., Bai, W., & Meng, Q. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1950192 · Cited by 31
Lipids and eicosanoids in fibrosis: emerging targets for therapy
Castelino, F. V. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328356d9f6 · Cited by 30
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 29
Development of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 28
Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model
Raja, A. A., Wakimoto, H., DeLaughter, D. M., Reichart, D., Gorham, J., Conner, D. A., Lun, M., Probst, C. K., Sakai, N., Knipe, R. S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204174119 · Cited by 27
Self-citationFunke-Chambour, M., Knudsen, L., Lagares, D., Ebener, S., Probst, C. K., Fontaine, B. A., Franklin, A., Kellner, M., Kühnel, M., Matthieu, S., et al. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0152oc · Cited by 27
Self-citationDruggable Lysophospholipid Signaling Pathways
Yanagida, K., & Valentine, W. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_7 · Cited by 27
Neighbors, M., Li, Q., Zhu, S., Liu, J., Wong, W. R., Jia, G., Sandoval, W. N., & Tew, G. W. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100375 · Cited by 26
miRNA-23a has effects to improve lung injury induced by sepsis in vitro and vivo study
Yang, J., Mao, M., & Zhen, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.097 · Cited by 24
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer
van Jaarsveld, M. T. M., Houthuijzen, J. M., & Voest, E. E. (2015) · Oncogene · doi:10.1038/onc.2015.467 · Cited by 22
Tomos, I. P., Kanellopoulou, P., Nastos, D., & Aidinis, V. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2471579 · Cited by 20
Suliman, H. B., Healy, Z. R., Zobi, F., Kraft, B. D., Welty‐Wolf, K. E., Smith, J. B., Barkauskas, C. E., & Piantadosi, C. A. (2021) · iScience · doi:10.1016/j.isci.2021.103535 · Cited by 20
RetractedAutotaxin and lysophosphatidic acid signalling in lung pathophysiology
Magkrioti, C. (2013) · World Journal of Respirology · doi:10.5320/wjr.v3.i3.77 · Cited by 20
Therapeutic targets and early stage clinical trials for pulmonary fibrosis
Sato, S., Yanagihara, T., & Kolb, M. R. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1554054 · Cited by 20
Zhou, Q., Chen, Y., Liang, Y., & Sun, Y. (2024) · Metabolites · doi:10.3390/metabo14060317 · Cited by 19
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis
Simonetti, J., Ficili, M., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2305126 · Cited by 18
Sivaraman, L., Gill, M., Nelson, D. M., & Chadwick, K. D. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115846 · Cited by 17
Kadam, A. H., & Schnitzer, J. E. (2024) · Cells · doi:10.3390/cells13060515 · Cited by 16
The lysophosphatidic acid axis in fibrosis: Implications for glaucoma
O’Regan, A., O'Brien, C. J., & Eivers, S. B. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12929 · Cited by 16
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)
Gu, Z., Yan, Y., Yao, H., Lin, K., & Li, X. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2130753 · Cited by 16
Shakeel, I., Afzal, M., Islam, A., Sohal, S. S., & Hassan, M. I. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100167 · Cited by 16
Bone Marrow-Derived Mononuclear Cell Therapy in Papain-Induced Experimental Pulmonary Emphysema
Machado, M. N., Mazzoli‐Rocha, F., Casquilho, N. V., Maron‐Gutierrez, T., Ortenzi, V. H., Morales, M. M., Fortunato, R. S., & Zin, W. A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00121 · Cited by 16
Kreuter, M., Maher, T. M., Wuyts, W. A., Valenzuela, C., Hamblin, M., Kim, S., Patel, A., Elpers, B., & Richeldi, L. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.04.003 · Cited by 15
Patil, R., Fells, J. I., Szabó, E., Lim, K. G., Norman, D. D., Balogh, A., Patil, S. A., Strobos, J., Miller, D. D., & Tigyi, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5007116 · Cited by 15
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
NAIR, G. B., Matela, A., Kurbanov, D., & Raghu, G. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1177461 · Cited by 14
Meng, G., Wuest, M., Tang, X., Dufour, J. H., McMullen, T. P. W., Wuest, F. R., Murray, D. L., & Brindley, D. N. (2020) · Cancers · doi:10.3390/cancers12040999 · Cited by 14
LI, J., Wang, G., & Sun, X. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1916 · Cited by 14
Dysregulation of lysophospholipid signaling by p53 in malignant cells and the tumor microenvironment
Lee, S. Ç., Lin, K., Balogh, A., Norman, D. D., Bavaria, M. N., Kuo, B., Yue, J., Balázs, L., Benyó, Z., & Tigyi, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109850 · Cited by 13
Sandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Hsia, I., Asmani, M., & Zhao, R. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115194 · Cited by 12
Maher, T. M., Song, J. W., Kramer, M. R., LANCASTER, L. H., Corte, T. J., Yun, J. H., Kim, K., Cho, J., Sather, L., George, P., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003038 · Cited by 12
Fibrosis in PCLS: comparing TGF-β and fibrotic cocktail
Machahua, C., Marti, T. M., Dorn, P., & Funke-Chambour, M. (2025) · Respiratory Research · doi:10.1186/s12931-025-03110-2 · Cited by 12
Birker, M., Boucher, M., Ranieri, G., Poirey, S., Studer, R. O., Freti, D., Schnoebelen, M., Froidevaux, S., Morrison, K., Wyss, C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103396 · Cited by 12
Dong, Y., Wu, Y., Cui, M., & Xu, X. (2017) · Mediators of Inflammation · doi:10.1155/2017/2754756 · Cited by 12
Targeting the epithelial cells in fibrosis: a new concept for an old disease
Moll, S., Chaykovska, L., Meier, M., Budd, D. C., Formentini, I., Pomposiello, S. I., & Prunotto, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.006 · Cited by 12
Li, Q., Wong, W. R., Birnberg, A., Chakrabarti, A., Yang, X., Choy, D. F., Olsson, J. K., Verschueren, E., Neighbors, M., Sandoval, W. N., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01670-9 · Cited by 11
Shen, X., Zou, J., Li, F., Zhang, T., & Guo, T. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8937 · Cited by 11
Metadata
- Authors
- Funke, M., Zhao, Z., Xu, Y., Chun, J., & Tager, A. M.
- Affiliations
- Harvard University (US)
- Indiana University School of Medicine (US)
- Scripps Research Institute (US)
- Corresponding author
- Tager, Andrew M.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-01
- Volume
- 46
- Issue
- 3
- Pages
- 355-364
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC3326436
- OpenAlex
- W2114232709
- Cited by
- 141
- References
- 49
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 8 · 2018: 11 · 2017: 5 · 2016: 10 · 2015: 10 · 2014: 8 · 2013: 11 · 2012: 14
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Funders
- National Institutes of Health (5r01da019674-05)
- National Heart, Lung, and Blood Institute (R01HL095732, R01HL108975)
- National Institute on Drug Abuse (NIH-DA019674, R01-DA019674)
- National Cancer Institute (R01CA095042)
- National Institute of Allergy and Infectious Diseases (P30AI060354)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH-HD050685, R01HD050685)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- lysophosphatidic acid, LPA1 receptor, epithelial apoptosis, lung injury, idiopathic pulmonary fibrosis, bleomycin-induced lung injury, anoikis, caspase-3, alveolar epithelial cells, bronchial epithelial cells, lung fibroblasts, LPA signaling
- MeSH terms
- Animals, Bleomycin, Cell Adhesion, Cells, Cultured, Disease Models, Animal, Epithelial Cells, Fibroblasts, Humans, Lung, Lysophospholipids, Mice, Inbred C57BL, Pulmonary Fibrosis, Time Factors, Signal Transduction, Apoptosis, Mice, Knockout, Anoikis, Receptors, Lysophosphatidic Acid, Mice, Rats, Caspase 3, Lung Injury, Mice, 129 Strain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.